{"id":787,"date":"2019-02-05T12:26:34","date_gmt":"2019-02-05T09:26:34","guid":{"rendered":"http:\/\/kliniki.webproposal.eu\/?page_id=787"},"modified":"2019-02-18T12:50:01","modified_gmt":"2019-02-18T09:50:01","slug":"endokrinologiko-protokolla","status":"publish","type":"page","link":"https:\/\/www.appk.gr\/en\/endokrinologiko-protokolla\/","title":{"rendered":"Endocrine \u2013 Clinical Trials and Research"},"content":{"rendered":"<p><strong>ENDOCRINOLOGY DEPARTMENT \u2013 CLINICAL TRIALS AND RESEARCH<\/strong><\/p>\n<p>European observational study of Pasireotide LAR in Megalacria \u2013 ACRONIS<br \/>\nCode: CSOM230CIC05<br \/>\nSupport: Novartis Pharma Services AG<\/p>\n<p>Effectiveness and safety observational study Afinitor\u00ae (everolimus) in patients with non surgically ressected or metastatic neuroendocrine pancreatic tumors G1 or G2 \u2013 PROTOR<br \/>\nCode: CRAD001PGR07<br \/>\nSupport: Novartis Pharma Services AG<\/p>\n<p>Double blind randomized controlled trial comparing effectiveness and safety of levoketoconazole (2S, 4R-ketoconazole) with placebo for the treatment of Endogenous Cushing Syndrome<br \/>\nCode: COR-2017-01<br \/>\nSupport: Cortendo AB<\/p>\n<p>ASPEN study: A Prospective Evaluation of the Management of Sporadic Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Neoplasms \u22642<\/p>\n<p>Evaluation of denosumab in adult patients with Langerhans mast cell disease: multicentre open-label clinical trial<br \/>\nCode: 20159460<\/p>\n<p>\u0391daptation of the existing EORTC QLQ-GINET21 module to develop a specific module for use in patients with Pancreatic Neuroendocrine Tumor, Phases I to III<\/p>\n<p>Clock gene expression in adrenal tumors (in association with the Biochemistry Research Laboratory, Medical School, E. Kassi)<\/p>\n<p>Factors in Neuroendocrine Tunors of the Gastrointestinal Tract<\/p>\n<p>Clock genes abnormalities in patients with autoimmune atrophic gastritis, hyperplasia of gastric muffin cells and carcinoid type I (in association with the Biochemistry Research Laboratory, Medical School, E. Kassi)<\/p>\n<p>Autophagy pathway in Neuroendocrine Tumors of the Pancreas (in association with the Experimental Surgical Unit of the Biomedical Research Academy of Athens, E. Andreakos<\/p>\n<p>Epigenetics and Osteoporosis (in association with the BioMedical Sciences Research Centre \u2013 251 Aviation Forces General Hospital, P. Makras)<\/p>\n<p>Disthrepsia and clinical outcome in patients with Neuroendocrine Tumors<\/p>\n<p>Sarcopenia in patients with Neuroendocrine Tumors<\/p>\n<p>\u03a4he clinical significance of metastatic bone disease in patients with advanced Gastrointestinal Neuroendocrine Tumors.<\/p>\n<p>Long term follow-up in patients with Appendiceal Neuroendocrine Tumors (Appendiceal NEN)<\/p>\n<p>Metastatic Gastric Neuroendocrine Neoplasms (NENs) type 1<\/p>\n<p>Tumorigenesis in Pituitary<\/p>\n<p>Comparative study of Magnetic Resonance Imaging (MRI) with Endoscopic Ultarsonography (EUS) in patients with Multiple Endocrine Neoplasia type 1 (MEN1)<\/p>\n<p>Lung Metastasis in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NET)<\/p>\n<p>Neuroendocrine tumors in Bone Metabolism<\/p>\n<p>Capecitabine and Temozolomide (CAPTEM) \u03c3\u03c4\u03bf\u03c5\u03c2 NETs<\/p>","protected":false},"excerpt":{"rendered":"<p>ENDOCRINOLOGY DEPARTMENT \u2013 CLINICAL TRIALS AND RESEARCH European observational study of Pasireotide LAR in Megalacria \u2013 ACRONIS Code: CSOM230CIC05 Support: Novartis Pharma Services AG Effectiveness and safety observational study Afinitor\u00ae (everolimus) in patients with non surgically ressected or metastatic neuroendocrine pancreatic tumors G1 or G2 \u2013 PROTOR Code: CRAD001PGR07 Support: Novartis Pharma Services AG Double [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ngg_post_thumbnail":0,"footnotes":""},"class_list":["post-787","page","type-page","status-publish"],"_links":{"self":[{"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/pages\/787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/comments?post=787"}],"version-history":[{"count":4,"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/pages\/787\/revisions"}],"predecessor-version":[{"id":1059,"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/pages\/787\/revisions\/1059"}],"wp:attachment":[{"href":"https:\/\/www.appk.gr\/en\/wp-json\/wp\/v2\/media?parent=787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}